MedTrace Logo

Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis

NCT01684540 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2026-01-29

No results posted yet for this study

Summary

This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin® Rhinitis Nasal Spray. In addition the effectiveness and safety shall be compared to a Sinupret forte. The patient applies Ectoin® Rhinitis Nasal Spray or takes Sinupret forte according to the instructions for use. The observation takes place over a period of 14 days. Response to treatment is recorded at day 7 and day 14 by the physician and in daily by the patient in a dairy.

Conditions

  • Sinusitis

Interventions

OTHER

Medical Device, Drug-like

Ectoin Rhinitis Nasal Spray

DRUG

Sinupret forte

Sponsors & Collaborators

  • Bitop AG

    lead INDUSTRY

Principal Investigators

  • Ralph Mösges, Prof. · Institut für Med. Informatik, Statistik und Epidemiologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01684540 on ClinicalTrials.gov